Subscribe
m-a-istock-537908812
designer491 / iStockphoto.com
3 April 2018Asia-Pacific

Takeda mulls Shire acquisition bid

Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.

More on this story

Americas
Shire welcomes Adderall generic ruling
27 March 2018   A US judge handed a win to Shire late last week, finding that a generic version of its attention deficit hyperactivity disorder drug Adderall XR would infringe Shire’s patents.
Biotechnology
Shire to sell oncology business for $2.4bn
17 April 2018   Biotech company Shire has revealed plans to sell its oncology business for $2.4 billion to France-based Servier.
Asia-Pacific
Takeda makes fourth offer to buy Shire
23 April 2018   Japan-based Takeda has upped its offer to buy Ireland-headquartered Shire for the fourth time, raising its bid to approximately £44 billion.

More features

Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic